This “TYK2 Kinase Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in TYK2 Kinase Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
TYK2 Kinase Inhibitors Understanding
Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also component of both the type I and type III interferon signaling pathways. Selective inhibition of Tyk2 can provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.
Report Highlights
This segment of the TYK2 Kinase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TYK2 Kinase Inhibitors Emerging Drugs
Deucravacitinib: Bristol-Myers Squibb
Deucravacitinib (formerly BMS 986165) is an orally available, selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. Bristol Myers Squibb is evaluating deucravacitinib in Phase 3 clinical studies in psoriasis.
Brepocitinib: Pfizer
Brepocitinib (PF-06700841) is a selective topical, tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) inhibitor. The drug is in phase 2 clinical studies for the potential treatment of psoriasis and Atopic dermatitis in topical formulation and, in oral formulation for psoriatic arthritis, Crohn's disease, Ulcerative colitis, vitiligo, systemic lupus erythematosus, Alopecia areata and hidradenitis suppurativa.
This segment of the report provides insights about the different TYK2 Kinase Inhibitors drugs segregated based on following parameters that define the scope of the report.
There are approx. 15+ key companies which are developing the TYK2 Kinase Inhibitors. The companies which have their TYK2 Kinase Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
TYK2 Kinase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TYK2 Kinase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TYK2 Kinase Inhibitors drugs.
Geography Covered
- Global coverage
TYK2 Kinase Inhibitors Understanding
TYK2 Kinase Inhibitors: Overview
Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine-protein kinase, an enzyme that in humans is encoded by the TYK2 gene. Tyk2, together with three other family subtypes, namely, Jak1, Jak2, and Jak3, belong to the JAK family. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also component of both the type I and type III interferon signaling pathways. Selective inhibition of Tyk2 can provide pharmacological benefits in the treatment of many diseases such as psoriasis, systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), rheumatoid arthritis (RA), cancer, and diabetes.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence TYK2 Kinase Inhibitors R&D. The therapies under development are focused on novel approaches for TYK2 Kinase Inhibitors.
TYK2 Kinase Inhibitors Emerging Drugs Chapters
This segment of the TYK2 Kinase Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
TYK2 Kinase Inhibitors Emerging Drugs
Deucravacitinib: Bristol-Myers Squibb
Deucravacitinib (formerly BMS 986165) is an orally available, selective allosteric inhibitor of tyrosine kinase 2 (Tyk2). Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease. Bristol Myers Squibb is evaluating deucravacitinib in Phase 3 clinical studies in psoriasis.
Brepocitinib: Pfizer
Brepocitinib (PF-06700841) is a selective topical, tyrosine kinase 2 (TYK2) and janus kinase 1 (JAK1) inhibitor. The drug is in phase 2 clinical studies for the potential treatment of psoriasis and Atopic dermatitis in topical formulation and, in oral formulation for psoriatic arthritis, Crohn's disease, Ulcerative colitis, vitiligo, systemic lupus erythematosus, Alopecia areata and hidradenitis suppurativa.
TYK2 Kinase Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different TYK2 Kinase Inhibitors drugs segregated based on following parameters that define the scope of the report.
Major Players working on TYK2 Kinase Inhibitors
There are approx. 15+ key companies which are developing the TYK2 Kinase Inhibitors. The companies which have their TYK2 Kinase Inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Bristol-Myers Squibb.
Phases
This report covers around 15+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
TYK2 Kinase Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
TYK2 Kinase Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses TYK2 Kinase Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging TYK2 Kinase Inhibitors drugs.
TYK2 Kinase Inhibitors Report Insights
- TYK2 Kinase Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
TYK2 Kinase Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Scenario and Emerging Therapies:
- How many companies are developing TYK2 Kinase Inhibitors drugs?
- How many TYK2 Kinase Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for TYK2 Kinase Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the TYK2 Kinase Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for TYK2 Kinase Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Incyte Corporation
- Bristol-Myers Squibb
- Oncostellae
- Pfizer
- Galapagos
- Haisco Pharmaceutical Group
- Sareum
- Oncostellae
Key Products
- Baricitinib
- Deucravacitinib
- OST-122
- Brepocitinib
- GLPG-3121
- FTP 637
- SDC-1801
- OST-246
Table of Contents
IntroductionExecutive Summary
TYK2 Kinase Inhibitors: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
TYK2 Kinase Inhibitors - Analytical Perspective
In-depth Commercial Assessment
- TYK2 Kinase Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
TYK2 Kinase Inhibitors Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Deucravacitinib: Bristol-Myers Squibb
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Brepocitinib: Pfizer
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
GLPG-3121 Galapagos
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
FTP 637: Haisco Pharmaceutical Group
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
TYK2 Kinase Inhibitors Key Companies
TYK2 Kinase Inhibitors Key Products
TYK2 Kinase Inhibitors- Unmet Needs
TYK2 Kinase Inhibitors- Market Drivers and Barriers
TYK2 Kinase Inhibitors- Future Perspectives and Conclusion
TYK2 Kinase Inhibitors Analyst Views
TYK2 Kinase Inhibitors Key Companies
AppendixList of Tables
Table 1 Total Products for TYK2 Kinase Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for TYK2 Kinase Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Companies Mentioned
A selection of companies mentioned in this report includes:
- Incyte Corporation
- Bristol-Myers Squibb
- Oncostellae
- Pfizer
- Galapagos
- Haisco Pharmaceutical Group
- Sareum
- Oncostellae
